Evidence map›Paper›PMID 30937696›Full record

ArticleVirus genes2019

Identification of a lytic Pseudomonas aeruginosa phage depolymerase and its anti-biofilm effect and bactericidal contribution to serum.

Liyuan Mi, Yannan Liu, Can Wang, Tongtong He, Shan Gao, Shaozhen Xing, Yong Huang, Hang Fan, Xianglilan Zhang, Wengong Yu and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Virus genes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 58 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Phage-Based Approaches to ChronicAntibiotics (Basel, Switzerland) · 2026
    Review
  6. Understanding phage Receptor-binding protein interaction with host surface receptor: the key for phage-Mediated detection and elimination of Pseudomonas aeruginosa.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Review
  7. Review
  8. The Ability of Bacteriophages to Reduce Biofilms Produced byAntibiotics (Basel, Switzerland) · 2025
    Article
  9. Article
  10. EngineeredFrontiers in microbiology · 2025
    Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Synergistic removal ofFrontiers in microbiology · 2024
    Article
  18. Review
  19. Article
  20. Infectious medicine · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Liyuan MiKey Laboratory of Marine Drugs, Chinese Ministry of Education; Key Laboratory of Glycoscience & Glycotechnology of Shandong Province; School of Medicine and Pharmacy; Laboratory for Marine Drugs and Bioproducts of Qingdao National Laboratory for Marine Science and Technology, Ocean University of China, 5 Yushan Road, Qingdao, 266003, China.
Yannan LiuDepartment of Respiratory and Critical Care Medicine, 307th Hospital of PLA, No. 8 Dongda Street, Fengtai District, Beijing, 100071, China.
Can WangDepartment of Respiratory and Critical Care Medicine, 307th Hospital of PLA, No. 8 Dongda Street, Fengtai District, Beijing, 100071, China.
Tongtong HeState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, 100071, China.
Shan GaoKey Laboratory of Marine Drugs, Chinese Ministry of Education; Key Laboratory of Glycoscience & Glycotechnology of Shandong Province; School of Medicine and Pharmacy; Laboratory for Marine Drugs and Bioproducts of Qingdao National Laboratory for Marine Science and Technology, Ocean University of China, 5 Yushan Road, Qingdao, 266003, China.
Shaozhen XingState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, 100071, China.
Yong HuangState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, 100071, China.
Hang FanState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, 100071, China.
Xianglilan ZhangState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, 100071, China.
Wengong YuKey Laboratory of Marine Drugs, Chinese Ministry of Education; Key Laboratory of Glycoscience & Glycotechnology of Shandong Province; School of Medicine and Pharmacy; Laboratory for Marine Drugs and Bioproducts of Qingdao National Laboratory for Marine Science and Technology, Ocean University of China, 5 Yushan Road, Qingdao, 266003, China.
Zhiqiang MiState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, 100071, China.
Yigang TongState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, 100071, China.
Changqing BaiDepartment of Respiratory and Critical Care Medicine, 307th Hospital of PLA, No. 8 Dongda Street, Fengtai District, Beijing, 100071, China. mlp1604@sina.com.
Feng HanKey Laboratory of Marine Drugs, Chinese Ministry of Education; Key Laboratory of Glycoscience & Glycotechnology of Shandong Province; School of Medicine and Pharmacy; Laboratory for Marine Drugs and Bioproducts of Qingdao National Laboratory for Marine Science and Technology, Ocean University of China, 5 Yushan Road, Qingdao, 266003, China. fhan@ouc.edu.cn.
Institute of Microbiology · CNQingdao National Laboratory for Marine Science and Technology · CN307th Hospital of Chinese People’s Liberation Army · CNOcean University of China · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pseudomonas aeruginosa (P. aeruginosa) infection has imposed a great threat to patients with cystic fibrosis. With the emergence of multidrug-resistant P. aeruginosa, developing an alternative anti-microbial strategy is indispensable and more urgent than ever. In this study, a lytic P. aeruginosa phage was isolated from the sewage of a hospital, and one protein was predicted as the depolymerase-like protein by genomic sequence analysis, it includes two catalytic regions, the Pectate lyase_3 super family and Glycosyl hydrolase_28 super family. Further analysis demonstrated that recombinant depolymerase-like protein degraded P. aeruginosa exopolysaccharide and enhanced bactericidal activity mediated by serum in vitro. Additionally, this protein disrupted host bacterial biofilms. All of these results showed that the phage-derived depolymerase-like protein has the potential to be developed into an anti-microbial agent that targets P. aeruginosa.

Indexed as

BiofilmsDrug Resistance, MultipleHumansPseudomonas aeruginosaPseudomonas InfectionsPseudomonas PhagesSewageSewageBacteriophageBiofilmDepolymeraseExopolysaccharidePseudomonas aeruginosa

Identifiers

PMID30937696
OpenAlexW2930637164

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.